DelveInsight’s “Constipation-Pipeline Insight, 2023” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Constipation pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Constipation Pipeline Report
-
Over 15+ companies and 15+ pipeline drugs in Constipation are in various stages of development, and their anticipated acceptance in the Constipation market would significantly increase market revenue.
-
Leading Constipation companies developing novel drug candidates to improve the Constipation treatment landscape include Anji Pharma, Yuhan, Theravance Biopharma, RaQualia Pharma, Process Pharmaceuticals, Abbott, AbbVie, and many others.
-
Promising Constipation pipeline therapies in various stages of development include YH 12852, RQ 00000010, RQ 00433412, and many others
Constipation Overview
Constipation is a condition in which you may have fewer than three bowel movements a week; stools that are hard, dry, or lumpy; stools that are difficult or painful to pass; or a feeling that not all stool has passed. In many patients, constipation is associated with sluggish movement of stool through the colon. This delay may be due to drugs, organic conditions, a disorder of defecatory function (ie, pelvic floor dysfunction), or a disorder that results from the diet. Certain findings raise suspicion of a more serious etiology of chronic constipation: Distended, tympanitic abdomen, vomiting, blood in stool, weight loss, and severe constipation of recent onset/worsening in older patients. Chronic constipation with modest abdominal discomfort in a patient who has used laxatives for a long time suggests slow-transit constipation.
Constipation Pipeline Analysis: Drug Profile
Pradigastat : Anji Pharma
ANJ908 (Pradigastat) has the potential to markedly improve the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome-associated constipation (IBS-C), two prevalent diseases with few effective treatments. The inhibition of DGAT1 by ANJ908 changes the intestinal milieu, namely by raising the level of fatty acids in the gut lumen. This leads to increased colon motility and water secretion, two necessary attributes for effective constipation therapy. Anji has initiated a Phase 2 trial of ANJ908 (pradigastat) in patients with functional constipation.
Discover more about the emerging Constipation drugs @ ConstipationTreatment Drugs
Constipation Pipeline Therapies and Key Companies
-
Pradigastat : Anji Pharma
-
YH 12852: Yuhan
-
RQ 00433412 : RaQualia Pharma
And many others
DelveInsight’s Report covers around 15+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I) along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Route of Administration
Constipation pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intra-articular
-
Intraocular
-
Intrathecal
-
Intravenous
-
Ophthalmic
-
Oral
-
Parenteral
-
Subcutaneous
-
Topical
-
Transdermal
Molecule Type
Products have been categorized under various Molecule types such as
-
Oligonucleotide
-
Peptide
-
Small molecule
Product Type
Drugs have been categorized under various product types like Mono, Combination, and Mono/Combination.
Scope of the Constipation Pipeline Report
-
Coverage: Global
-
Key Constipation Companies: Anji Pharma, Yuhan, Theravance Biopharma, RaQualia Pharma, Process Pharmaceuticals, Abbott Pharma, and many others.
-
Key Constipation Pipeline Therapies: YH 12852, RQ 00000010, RQ 00433412, and many others
Find out more about the Constipation treatment options in development @ Constipation Clinical Trials
Table of Contents
1. Constipation Introduction
2. Constipation Executive Summary
3. Constipation Overview
4. Constipation Pipeline Therapeutics
5. Constipation Late-Stage Products (Phase III)
6. Constipation Mid-Stage Products (Phase II)
7. Constipation Early Stage Products (Phase I/II)
8. Constipation Preclinical Stage Products
9. Constipation Discovery Stage Products
10. Constipation Therapeutic Assessment
11. Constipation Inactive Products
12. Constipation Collaborations Assessment- Licensing / Partnering / Funding
13. Constipation Unmet Needs
14. Constipation Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services